Planned Parenthood Accused of Miscoding Visits Tied to Cross-Sex Hormones

What the private review found

Do No Harm’s announcement describes an analysis of claims from 2015 through 2025, conducted with a private data broker. Researchers linked office-visit claims with hormone-prescription claims appearing within 30 days afterward.

The larger sample included approximately 5,700 patients age 22 or younger and 11,000–12,000 apparently gender-related prescriptions. Within it, the group flagged about 800 patients associated with 1,100–1,200 prescriptions it considered seemingly related to gender dysphoria and potentially paired with incorrect visit codes. Those numbers describe suspected discrepancies, not proven fraudulent transactions.

Why the limitations matter

The complaint acknowledges that the broker lacked the affiliates’ internal records. A prescription occurring shortly after a visit does not, by itself, prove that the prescription originated at that appointment. The association between a prescriber and an affiliate was also inferred from billing patterns rather than conclusively verified.

The group argues that visits lacked gender-dysphoria-related codes and instead used alternatives, including codes for an unspecified endocrine disorder or drug-level monitoring. Whether a particular code accurately describes an encounter requires the underlying records; the complaint expressly says its data cannot confirm misconduct.

Do No Harm wants investigators to examine both the coding and any resulting federal reimbursement. The available review does not establish a count or dollar total of improper federal payments. It would therefore be inaccurate to describe the flagged prescriptions as a verified taxpayer-funded fraud scheme.

What has—and has not—happened next

As of September 24, FaithfulHeartbeat had not located a public HHS announcement opening the investigation requested in this complaint. A watchdog’s submission and a government decision to investigate are separate events.

EWTN News reported on September 23 that Planned Parenthood did not respond to its request for comment. That was EWTN’s outreach, not an interview conducted by FaithfulHeartbeat.

For context, Planned Parenthood Southeastern Pennsylvania’s published service page defends gender-affirming hormone care and currently advertises it for patients 18 and older. That general description is not a response to this complaint, does not establish how other affiliates operated during the review period, and does not resolve the coding allegations.

FaithfulHeartbeat perspective: demand transparency, follow the evidence

From our Christian conservative perspective, protecting young people and holding medical institutions accountable are serious moral responsibilities. Patients, families and taxpayers deserve an honest account of the services being provided and billed. Political influence should never shield an institution from legitimate scrutiny.

These allegations deserve careful examination of the actual records. But our commitment to truth also means refusing to turn suspicion into a verdict. Accountability requires establishing what happened, which rules applied, and whether anyone knowingly sought payment improperly—not simply repeating the strongest accusation.